Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06196827
PHASE1

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Sponsor: Innostellar Biotherapeutics Co.,Ltd

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.

Official title: A Multi-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of rAAV2-RPE65 Gene Therapy (LX101) in Subjects With Biallelic RPE65 Mutation-associated Inherited Retinal Dystrophy

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

9

Start Date

2022-07-02

Completion Date

2027-12

Last Updated

2026-03-06

Healthy Volunteers

No

Interventions

GENETIC

LX101

Subretinal Administration

Locations (2)

Beijing Tongren Hospital, Capital Medical University

Beijing, China

Shanghai General Hospital

Shanghai, China